ERBB2 and breast carcinoma: Young patients with HER2-enriched breast cancer had significantly inferior outcome compared to older patients with HER2-enriched breast cancer (Figure 1; HR = 1.83, p = 0.003) and 10-year survival is 16.7% versus 50.0% for young vs. older patients, respectively.